Future Peptide Regulation: What Could Change Next

Two tracks moving in opposite directions

In 2023 and 2024, US regulators steadily closed off legal routes to the peptides lifters use. In 2026 the direction changed. In April, FDA took 12 peptides off its list of compounding substances flagged for significant safety risks. In July, its Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of them for the list of substances pharmacies may compound from.

At the same time, FDA kept sending warning letters to websites that sell peptides labeled "for research use only". So the outlook as of October 2026 isn't one steady squeeze. A prescription route through compounding pharmacies may open for a handful of peptides, while the gray market most buyers use faces more enforcement, not less. Sports rules run on a separate track: USADA says WADA's 2027 Prohibited List, in force from January 1, 2027, names peptides in general under its catch-all S0 class.

The predictions below are our reading of public FDA and WADA documents and law-firm commentary, not inside information. For what has already happened to sellers, see recent peptide enforcement cases.

How the compounding rules work

US clinics that prescribe peptides have mostly relied on 503A compounding pharmacies, which prepare drugs for individual patients. Under section 503A of the Food, Drug, and Cosmetic Act, a pharmacy may compound from a bulk substance only if it has a USP monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Most research peptides meet none of those tests. (Our legal landscape overview explains how this drug framework differs from the controlled-substance rules for steroids.)

While FDA reviews nominations for that list, it sorts substances into interim categories. Category 1 substances can be compounded under enforcement discretion during review. Category 2 substances carry a "significant safety risks" label, which a 2026 Orrick client alert notes had been the basis for FDA action against compounders. Larger outsourcing facilities work under a separate 503B list with its own categories.

The biologics claim, corrected

A claim that still circulates is that FDA reclassified ipamorelin and tesamorelin as biologics to block compounding. That's only partly right, and the two cases differ.

Tesamorelin's change came from a 2009 law, not a peptide crackdown. Under the Biologics Price Competition and Innovation Act, proteins became biological products, and on March 23, 2020, approved drug applications for them were deemed biologics licenses. FDA says the change doesn't affect peptides, which it defines as 40 or fewer amino acids. Tesamorelin is long enough to count as a protein, and FDA's list of transitioned products includes Egrifta. Theratechnologies describes the March 2025 approval of Egrifta WR as a supplemental biologics license application.

Ipamorelin, a five-amino-acid peptide, was never treated as a biologic. FDA handled it as an ordinary bulk drug substance. Its 503A nomination went to the PCAC in October 2024, and FDA's Category 2 page still lists ipamorelin acetate under the 503B interim policy, citing deaths in an intravenous study for gastric motility. Orrick notes that when peptides were withdrawn from Category 2 in that earlier period and sent to the PCAC, the committee recommended against listing each one.

The 2026 reversal

HHS Secretary Robert F. Kennedy Jr. signaled the shift in February 2026, and on April 15 the removal of 12 peptides from Category 2 was confirmed after their nominators withdrew them: BPC-157, TB-500, MOTS-c, injectable GHK-Cu, melanotan II, semax, PEG-MGF, DSIP (emideltide), epitalon, KPV, LL-37 and dihexa. Both Orrick and McDermott stress that leaving Category 2 doesn't put a substance in Category 1 or on the bulks list. These peptides sit in no category.

At the July 23-24, 2026 PCAC meeting, according to McDermott's account:

• BPC-157, KPV and TB-500 were each recommended 8-6 with one abstention.
• MOTS-c was recommended 7-5 with two abstentions.
• Epitalon and semax were recommended by similar margins.
• DSIP was not recommended (6 yes, 7 no, 1 abstention).

The other five (GHK-Cu, dihexa, LL-37, PEG-MGF and melanotan II) go to a second PCAC meeting before the end of February 2027.

A PCAC vote is advice. FDA still has to run notice-and-comment rulemaking; McDermott expects proposed rules in late 2026 or 2027, possibly followed by a multi-year process, and notes FDA could signal interim enforcement discretion. As of October 2026, we found no proposed rule in the Federal Register.

Even a final listing would be narrow. It would let licensed pharmacies compound these peptides for individual patients with a valid prescription. It wouldn't make research-use-only sales legal, and it wouldn't be a drug approval. State boards also matter: McDermott reports that Ohio's Board of Pharmacy has acted against pharmacies compounding peptides that federal rules don't yet allow, including BPC-157 and CJC-1295 with ipamorelin.

Enforcement against research-use-only sellers

The gray market is moving the other way. An August 24, 2026 FDA warning letter to Tex Peptides calls the site's semaglutide, tirzepatide, retatrutide, SS-31, tesamorelin and PT-141 products unapproved new drugs, and lists its bacteriostatic water too. FDA treated the site's descriptions of what each compound does as evidence of intended use as drugs. Our read, not FDA's stated position, is that a legal prescription channel for a few peptides will make unlicensed sellers easier targets, not harder ones.

Sport: the list that changes every January

WADA's 2026 Prohibited List is in force now. BPC-157 is named in S0, the class for substances with no current approval by any government health authority for human therapeutic use. TB-500 sits in S2.3 as a derivative of thymosin beta-4. CJC-1295, sermorelin and tesamorelin are named as GHRH analogues under S2.2.4, and ipamorelin and ibutamoren (MK-677) are named there as growth hormone secretagogues. SARMs are banned under S1.2.

USADA's advisory on the 2027 list says peptides in general are now named in S0, and that an unnamed peptide may still be prohibited. A 503A listing isn't a drug approval, so it wouldn't take any of these peptides out of S0. For tested athletes, the compounding changes make no difference.

Outlook by peptide group

Why few peptides take the drug-approval route

Full approval, the route tesamorelin and bremelanotide took, is expensive. A 2020 JAMA study of drugs approved from 2009 to 2018 estimated a median of about $985 million in research and development spending per new medicine, with a mean of about $1.3 billion.

Patents are the usual explanation for why so few research peptides attempt it: many are short sequences published decades ago, which makes exclusive rights harder to secure. That's plausible, but we found no data measuring it for these compounds.

The evidence gap is the other obstacle. A 2025 systematic review of BPC-157 in orthopedic sports medicine found 36 eligible studies, 35 of them preclinical, and no clinical safety data. A favorable PCAC vote doesn't change that.

Comparison table

The history behind these different tracks is covered in our history of performance-enhancer laws, and other countries' rules are in our international regulatory comparison.

What to watch next

• Federal Register: a proposed rule adding the July-recommended peptides to the 503A bulks list, or an FDA statement on interim enforcement discretion.
• Second PCAC meeting: due before the end of February 2027, covering GHK-Cu, melanotan II, LL-37, dihexa and PEG-MGF.
• WADA 2027 list: takes effect January 1, 2027.
• State pharmacy boards: Ohio has already acted, and other states may follow or diverge.
• Warning letters: whether FDA's August 2026 approach spreads to more research-use-only sellers.